Talks
ADA 2026: CagriSema REIMAGINE-3 Results
June 15, 2026
Share
ADA 2026: CagriSema REIMAGINE-2 Results
June 15, 2026
Share
ADA 2026: CagriSema REIMAGINE-1 Study Results
June 15, 2026
Share
ADA 2026: Retatrutide TRIUMPH-1 Trial
June 15, 2026
Share
ADA 2026: Zenagamtide
June 15, 2026
Share
ADA 2026: Elecoglipron VISTA Obesity Trial
June 15, 2026
Share
ADA 2026: Elecoglipron SOLSTICE Trial
June 15, 2026
Share
ADA 2026: Amylin Symposium
May 24, 2026
Share
ADA 2026: Amylin Symposium
May 24, 2026
Share
GLP-1RA Gene Therapy for T2D
May 24, 2026
Share
GLP-1RA Gene Therapy for T2D
May 24, 2026
Share
Hidden CGM Patterns & AI-Powered Algorithms to Predict T2D
May 24, 2026
Share
Hidden CGM Patterns & AI-Powered Algorithms to Predict T2D
May 24, 2026
Share
Continued High Rate of Death Due to Diabetes & Metabolic Conditions
May 24, 2026
Share
Continued High Rate of Death Due to Diabetes & Metabolic Conditions
May 24, 2026
Share
Tandem's First Tubeless Device
May 24, 2026
Share
Tandem's First Tubeless Device
May 24, 2026
Share
Finerenone Benefits in T2D & CKD
May 24, 2026
Share
Finerenone Benefits in T2D & CKD
May 24, 2026
Share
GLP-1RA Bridge Program: Prediabetes
May 24, 2026
Share
GLP-1RA Bridge Program: Prediabetes
May 24, 2026
Share
GLP-1RA & Pancreatitis
May 24, 2026
Share
GLP-1RA & Pancreatitis
May 24, 2026
Share
GLP-1RAs + PPIs
May 24, 2026
Share
GLP-1RAs + PPIs
May 24, 2026
Share
Polyendocrine Metabolic Ovarian Syndrome
May 24, 2026
Share
Polyendocrine Metabolic Ovarian Syndrome
May 24, 2026
Share
ECO 2026: Orforglipron
May 24, 2026
Share
ECO 2026: Orforglipron
May 24, 2026
Share
Teplizumab Expanded Approval
April 27, 2026
Share
Teplizumab Expanded Approval
April 27, 2026
Share
Ketogenic Diet Impact on Beta-Cell Function
April 27, 2026
Share
Ketogenic Diet Impact on Beta-Cell Function
April 27, 2026
Share
PIONEER-TEENS Supports Efficacy & Safety of Oral Semaglutide in Children
April 27, 2026
Share
PIONEER-TEENS Supports Efficacy & Safety of Oral Semaglutide in Children
April 27, 2026
Share
Orforglipron (Foundayo) Cuts CV Risk & All-Cause Mortality
April 27, 2026
Share
Orforglipron (Foundayo) Cuts CV Risk & All-Cause Mortality
April 27, 2026
Share
Tirzepatide Beats Dulaglutide for Cardiorenal Endpoints
April 27, 2026
Share
Tirzepatide Beats Dulaglutide for Cardiorenal Endpoints
April 27, 2026
Share
Implantable & Ultra-Long-Acting GLP1RA
April 27, 2026
Share
Implantable & Ultra-Long-Acting GLP1RA
April 27, 2026
Share
Delay in Statin Therapy in T2D
April 27, 2026
Share
Delay in Statin Therapy in T2D
April 27, 2026
Share
VESALIUS-CV: Reduced CV Risk in T2D with Evolocumab
April 27, 2026
Share
VESALIUS-CV: Reduced CV Risk in T2D with Evolocumab
April 27, 2026
Share
Once-Weekly Insulin Icodec (Awiqli) Approved for T2D
April 27, 2026
Share
Once-Weekly Insulin Icodec (Awiqli) Approved for T2D
April 27, 2026
Share
Improved Glycemic Control with CGM
April 26, 2026
Share
Improved Glycemic Control with CGM
April 26, 2026
Share
Triple-Agonist UBT251 Data
March 26, 2026
Share
Triple-Agonist UBT251 Data
March 26, 2026
Share
GLP-1RA Cessation: CV Risk
March 26, 2026
Share
GLP-1RA Cessation: CV Risk
March 26, 2026
Share
GLP-1RA Cessation: T1D Glycemic Control
March 26, 2026
Share
GLP-1RA Cessation: T1D Glycemic Control
March 26, 2026
Share
GLP-1RA and SUD
March 26, 2026
Share
GLP-1RA and SUD
March 26, 2026
Share
Trends in National Expenditure on Diabetes Therapies
March 26, 2026
Share
Trends in National Expenditure on Diabetes Therapies
March 26, 2026
Share
GLP1-RAs & Vision-Related Issues
March 26, 2026
Share
Close button
Why are you reporting this TALK?